Biotech | January 18, 2022
Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
The primary objective of the ongoing trial is to determine whether ambrisentan can prevent the progression to respiratory failure and reduce the need for mechanical ventilation, among others
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
The product will be commercialized from Unichem's Ghaziabad plant
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
